{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:53:00Z","timestamp":1792633980290,"version":"4.5.0"},"reference-count":180,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioengineering"],"abstract":"<jats:p>Neurodegenerative diseases (NDDs) are incurable and debilitating conditions that result in progressive degeneration and\/or death of nerve cells in the central nervous system (CNS). Identification of viable therapeutic targets and new treatments for CNS disorders and in particular, for NDDs is a major challenge in the field of drug discovery. These difficulties can be attributed to the diversity of cells involved, extreme complexity of the neural circuits, the limited capacity for tissue regeneration, and our incomplete understanding of the underlying pathological processes. Drug discovery is a complex and multidisciplinary process. The screening attrition rate in current drug discovery protocols mean that only one viable drug may arise from millions of screened compounds resulting in the need to improve discovery technologies and protocols to address the multiple causes of attrition. This has identified the need to screen larger libraries where the use of efficient high-throughput screening (HTS) becomes key in the discovery process. HTS can investigate hundreds of thousands of compounds per day. However, if fewer compounds could be screened without compromising the probability of success, the cost and time would be largely reduced. To that end, recent advances in computer-aided design, in silico libraries, and molecular docking software combined with the upscaling of cell-based platforms have evolved to improve screening efficiency with higher predictability and clinical applicability. We review, here, the increasing role of HTS in contemporary drug discovery processes, in particular for NDDs, and evaluate the criteria underlying its successful application. We also discuss the requirement of HTS for novel NDD therapies and examine the major current challenges in validating new drug targets and developing new treatments for NDDs.<\/jats:p>","DOI":"10.3390\/bioengineering8020030","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T12:40:16Z","timestamp":1614084016000},"page":"30","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":201,"title":["High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-4366","authenticated-orcid":false,"given":"Hasan","family":"Aldewachi","sequence":"first","affiliation":[{"name":"Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK"},{"name":"College of Pharmacy, Nineveh University, Mosul 41002, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2067-4531","authenticated-orcid":false,"given":"Radhwan N.","family":"Al-Zidan","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Mosul, Mosul 41002, Iraq"},{"name":"School of Applied Sciences, Edinburgh Napier University, Edinburgh EH11 4BN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Conner","sequence":"additional","affiliation":[{"name":"School of Sciences, Research Institute in Healthcare Science, University of Wolverhampton, Wolverhampton WV1 1LY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5683-1706","authenticated-orcid":false,"given":"Mootaz M.","family":"Salman","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Mosul, Mosul 41002, Iraq"},{"name":"Oxford Parkinson\u2019s Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Thomford, N.E., Senthebane, D.A., Rowe, A., Munro, D., Seele, P., Maroyi, A., and Dzobo, K. (2018). Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061578"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1359-6446(00)01511-7","article-title":"Strategies for discovering drugs from previously unexplored natural products","volume":"5","author":"Harvey","year":"2000","journal-title":"Drug Discov. Today"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1039\/C6MD00129G","article-title":"The evolution of drug discovery: From phenotypes to targets, and back","volume":"7","year":"2016","journal-title":"MedChemComm"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1021\/acschembio.9b00714","article-title":"A Point of Inflection and Reflection on Systems Chemical Biology","volume":"14","author":"Johnson","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2020.01.025","article-title":"Click Chemistry in Proteomic Investigations","volume":"180","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Maciejczyk, M., Zalewska, A., and Gerreth, A.K. (2020). Salivary Redox Biomarkers in Selected Neurodegenerative Diseases. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020497"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rabanel, J.-M., Perrotte, M., and Ramassamy, C. (2019). Nanotechnology at the Rescue of Neurodegenerative Diseases: Tools for Early Diagnostic. Nanobiotechnology in Neurodegenerative Diseases, Springer International Publishing.","DOI":"10.1007\/978-3-030-30930-5_2"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/1570159X16666180315142137","article-title":"Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design","volume":"16","author":"Sehgal","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/138620708783877753","article-title":"High Throughput Screening for Neurodegeneration and Complex Disease Phenotypes","volume":"11","author":"Varma","year":"2008","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/jnc.14829","article-title":"The energetic brain\u2014A review from students to students","volume":"151","author":"Bordone","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrd3373","article-title":"Cell death assays for drug discovery","volume":"10","author":"Kepp","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/cdd.2008.28","article-title":"No death without life: Vital functions of apoptotic effectors","volume":"15","author":"Galluzzi","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.conb.2009.10.002","article-title":"High-content screening of primary neurons: Ready for prime time","volume":"19","author":"Daub","year":"2009","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/B978-0-12-391856-7.00041-X","article-title":"High-Throughput Screening in Primary Neurons","volume":"Volume 506","author":"Sharma","year":"2012","journal-title":"Methods in Enzymology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/s41591-018-0140-5","article-title":"Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent","volume":"24","author":"Fujimori","year":"2018","journal-title":"Nat. Med."},{"key":"ref_17","first-page":"768","article-title":"A network dysfunction perspective on neurodegenerative diseases","volume":"443","author":"Palop","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp-2011-301782","article-title":"Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis","volume":"83","author":"Kanai","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awl024","article-title":"Altered axonal excitability properties in amyotrophic lateral sclerosis: Impaired potassium channel function related to disease stage","volume":"129","author":"Kanai","year":"2006","journal-title":"Brain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/jamaneurol.2013.136","article-title":"Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease","volume":"70","author":"Vossel","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_21","first-page":"31","article-title":"Cell-based assays in high-throughput screening for drug discovery","volume":"1","author":"Zang","year":"2012","journal-title":"Int. J. Biotechnol. Wellness Ind."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1359-6446(03)02752-1","article-title":"Highly sensitive fluorescence detection technology currently available for HTS","volume":"8","author":"Eggeling","year":"2003","journal-title":"Drug Discov. Today"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"An, W.F., and Tolliday, N.J. (2009). Introduction: Cell-Based Assays for High-Throughput Screening, Springer International Publishing.","DOI":"10.1007\/978-1-60327-545-3_1"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/17460441.2017.1364727","article-title":"Perspectives on optical biosensor utility in small-molecule screening","volume":"12","author":"Kaminski","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/acssensors.6b00735","article-title":"Harnessing the Versatility of Optical Biosensors for Target-Based Small-Molecule Drug Discovery","volume":"2","author":"Kaminski","year":"2016","journal-title":"ACS Sens."},{"key":"ref_26","first-page":"270","article-title":"Design and Implementation of High Throughput Screening Assays","volume":"47","author":"Hertzberg","year":"2010","journal-title":"Mol. Biotechnol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"El Harrad, L., Bourais, I., Mohammadi, H., and Amine, A. (2018). Recent Advances in Electrochemical Biosensors Based on Enzyme Inhibition for Clinical and Pharmaceutical Applications. Sensors, 18.","DOI":"10.3390\/s18010164"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1021\/acssensors.9b00827","article-title":"Compact Grating-Coupled Biosensor for the Analysis of Thrombin","volume":"4","author":"Kotlarek","year":"2019","journal-title":"ACS Sens."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/1573411014666180319152853","article-title":"Recent Advances in Biosensors Based Nanostructure for Pharmaceutical Analysis","volume":"15","author":"Pourbasheer","year":"2019","journal-title":"Curr. Anal. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1476-5381.2009.00604.x","article-title":"Ligand binding assays at equilibrium: Validation and interpretation","volume":"161","author":"Hulme","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.chembiol.2004.08.026","article-title":"A Flexible Data Analysis Tool for Chemical Genetic Screens","volume":"11","author":"Kelley","year":"2004","journal-title":"Chem. Biol."},{"key":"ref_32","unstructured":"Lo, D.C., and Hughes, R.E. (2011). High-Throughput and High-Content Screening for Huntington\u2019s Disease Therapeutics. Neurobiology of Huntington\u2019s Disease: Applications to Drug Discovery, CRC Press."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cader, Z., Graf, M., Burcin, M., Mandenius, C.-F., and Ross, J.A. (2019). Cell-Based Assays Using Differentiated Human Induced Pluripotent Cells, Springer International Publishing.","DOI":"10.1007\/978-1-4939-9477-9_1"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mandenius, C.-F., and Ross, J.A. (2019). Cell-Based Assays Using IPSCs for Drug Development and Testing, Springer.","DOI":"10.1007\/978-1-4939-9477-9"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.snb.2016.01.011","article-title":"Unified 2D and 3D cell-based high-throughput screening platform using a micropillar\/microwell chip","volume":"228","author":"Lee","year":"2016","journal-title":"Sens. Actuators B Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drudis.2018.07.007","article-title":"Translational in vitro research: Integrating 3D drug discovery and development processes into the drug development pipeline","volume":"24","author":"Kelm","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_37","unstructured":"Goodnow, R.A. (2017). Chapter Five\u2014High-Throughput Screening, in Annual Reports in Medicinal Chemistry, Academic Press."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1039\/C5OB02233A","article-title":"Accelerated cellular on- and off-target screening of bioactive compounds using microarrays","volume":"14","author":"Fu","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4014\/jmb.1508.08007","article-title":"Cell-Based Assay Design for High-Content Screening of Drug Candidates","volume":"26","author":"Nierode","year":"2016","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-9624-7_5","article-title":"A High-Throughput System for Transient and Stable Protein Production in Mammalian Cells","volume":"Volume 2025","author":"Rue","year":"2019","journal-title":"Methods in Molecular Biology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pep.2017.08.002","article-title":"Rapid characterization of the CHO platform cell line and identification of pseudo attP sites for PhiC31 integrase","volume":"140","author":"Damavandi","year":"2017","journal-title":"Protein Expr. Purif."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16873","DOI":"10.1074\/jbc.M115.646034","article-title":"Identification and Molecular Mechanisms of the Rapid Tonicity-induced Relocalization of the Aquaporin 4 Channel","volume":"290","author":"Kitchen","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1111\/ejn.13723","article-title":"Hypothermia increases aquaporin 4 (AQP4) plasma membrane abundance in human primary cortical astrocytes via a calcium\/transient receptor potential vanilloid 4 (TRPV4)-and calmodulin-mediated mechanism","volume":"46","author":"Salman","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.cell.2020.03.037","article-title":"Targeting Aquaporin-4 Subcellular Localization to Treat Central Nervous System Edema","volume":"181","author":"Kitchen","year":"2020","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"183573","DOI":"10.1016\/j.bbamem.2021.183573","article-title":"The effects of trifluoperazine on brain edema, aquaporin-4 expression and metabolic markers during the acute phase of stroke using photothrombotic mouse model","volume":"1863","author":"Sylvain","year":"2021","journal-title":"Biochim. Biophys. Acta BBA Biomembr."},{"key":"ref_46","first-page":"29","article-title":"Cell-Based Assays to Probe the ERK MAP Kinase Pathway in Endothelial Cells","volume":"Volume 486","author":"Wyler","year":"2009","journal-title":"Advanced Structural Safety Studies"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1093\/hmg\/ddq142","article-title":"Current status on Alzheimer disease molecular genetics: From past, to present, to future","volume":"19","author":"Bettens","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1093\/hmg\/ddq167","article-title":"Parkinson\u2019s disease: Insights from pathways","volume":"19","author":"Cookson","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.mcn.2016.01.011","article-title":"Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models","volume":"73","author":"Haggarty","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cels.2018.10.013","article-title":"Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model","volume":"7","author":"Kessler","year":"2018","journal-title":"Cell Syst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/17460441.2012.715631","article-title":"Ligand\u2013receptor interaction platforms and their applications for drug discovery","volume":"7","author":"Fang","year":"2012","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1111\/bph.13316","article-title":"Fluorescence-and bioluminescence-based approaches to study GPCR ligand binding","volume":"173","author":"Stoddart","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mcn.2013.03.001","article-title":"TDP-43 high throughput screening analyses in neurodegeneration: Advantages and pitfalls","volume":"56","author":"Buratti","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_54","unstructured":"Ballatore, C., Brunden, K., Crowe, A., Huryn, D., Lee, V., Trojanowski, J., Smith, A., Huang, R., Huang, W., and Johnson, R. (2011). Aminothienopyridazine Inhibitors of Tau Assembly. (WO2011037985 A8), Patent."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.expneurol.2009.08.031","article-title":"Tau-directed drug discovery for Alzheimer\u2019s disease and related tauopathies: A focus on tau assembly inhibitors","volume":"223","author":"Brunden","year":"2010","journal-title":"Exp. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.drudis.2019.08.001","article-title":"A human-on-a-chip approach to tackling rare diseases","volume":"24","author":"Rumsey","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Khan, N.I., and Song, E. (2020). Lab-on-a-Chip Systems for Aptamer-Based Biosensing. Micromachines, 11.","DOI":"10.3390\/mi11020220"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and challenges in phenotypic drug discovery: An industry perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"MaCarron","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.bjp.0707373","article-title":"Origin and evolution of high throughput screening","volume":"152","author":"Pereira","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","article-title":"The economic cost of brain disorders in Europe","volume":"19","author":"Olesen","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.euroneuro.2011.09.005","article-title":"The full cost and burden of disorders of the brain in Europe exposed for the first time","volume":"21","author":"Nutt","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1359-6446(01)02082-7","article-title":"Why is the global CNS pharmaceutical market so under-penetrated?","volume":"7","author":"Pardridge","year":"2002","journal-title":"Drug Discov. Today"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"573775","DOI":"10.3389\/fbioe.2020.573775","article-title":"Design and Validation of a Human Brain Endothelial Microvessel-on-a-Chip Open Microfluidic Model Enabling Advanced Optical Imaging","volume":"8","author":"Salman","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: Bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/cc9800071","article-title":"A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases","volume":"1","author":"Ghose","year":"1999","journal-title":"J. Comb. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009\u20132018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: Few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","article-title":"Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010-2015","volume":"26","author":"Mehta","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_73","unstructured":"Biogen (2021, February 23). 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02484547."},{"key":"ref_74","unstructured":"Bloomberg (2021, February 23). Biogen to Spend $2.5 Billion Before Alzheimer\u2019s Drug Results, in 2015. Available online: https:\/\/www.bloomberg.com\/news\/articles\/2015-04-27\/biogen-to-spend-2-5-billion-before-alzheimer-s-drug-results."},{"key":"ref_75","unstructured":"Biogen (2021, February 23). 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477800."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: New estimates of drug development costs","volume":"22","author":"Hansen","year":"2003","journal-title":"J. Health Econ."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","article-title":"Cost of disorders of the brain in Europe 2010","volume":"21","author":"Gustavsson","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_78","unstructured":"DiMasi, J. (2021, February 23). CNS Drugs Take Longer to Develop, Have Lower Success Rates, than Other Drugs. Tufts Center for the Study of Drug Development Website. Available online: http:\/\/csdd.tufts.edu\/news\/complete_story\/pr_ir_nov_dec_ir."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","article-title":"The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes","volume":"120","author":"Gribkoff","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_80","first-page":"5","article-title":"20% Longer to Develop and to Approve vs. Non-CNS Drugs","volume":"20","author":"Take","year":"2018","journal-title":"Tufts CSDD Impact Rep."},{"key":"ref_81","first-page":"638","article-title":"Schizophrenia: Overview and Treatment Options","volume":"39","author":"Patel","year":"2014","journal-title":"P T A Peer-Rev. J. Formul. Manag."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1128\/JVI.79.8.5174-5184.2005","article-title":"Comparison of Inflammatory and Acute-Phase Responses in the Brain and Peripheral Organs of the ME7 Model of Prion Disease","volume":"79","author":"Cunningham","year":"2005","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(97)02073-4","article-title":"Conformational disease","volume":"350","author":"Carrell","year":"1997","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eaaz6014","DOI":"10.1126\/sciadv.aaz6014","article-title":"Complete aggregation pathway of amyloid \u03b2 (1-40) and (1-42) resolved on an atomically clean interface","volume":"6","author":"Nirmalraj","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/jclinpath-2019-205952","article-title":"Molecular pathology of neurodegenerative diseases: Principles and practice","volume":"72","author":"Kovacs","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1021\/ac400023c","article-title":"Analysis of Protein Aggregation in Neurodegenerative Disease","volume":"85","author":"Pedersen","year":"2013","journal-title":"Anal. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/glia.22575","article-title":"Glial influence on the blood brain barrier","volume":"61","author":"Alvarez","year":"2013","journal-title":"Glia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.expneurol.2018.07.009","article-title":"Glia-neuron energy metabolism in health and diseases: New insights into the role of nervous system metabolic transporters","volume":"309","author":"Jha","year":"2018","journal-title":"Exp. Neurol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Hussain, R., Zubair, H., Pursell, S., and Shahab, M. (2018). Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sci., 8.","DOI":"10.3390\/brainsci8090177"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijbiomac.2017.07.116","article-title":"A review on protein misfolding, aggregation and strategies to prevent related ailments","volume":"105","author":"Shamsi","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Abir-Awan, M., Kitchen, P., Salman, M.M., Conner, M.T., Conner, A.C., and Bill, R.M. (2019). Inhibitors of Mammalian Aquaporin Water Channels. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071589"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: A source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1476-5381.2011.01299.x","article-title":"Animal models in the drug discovery pipeline for Alzheimer\u2019s disease","volume":"164","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lfs.2014.05.017","article-title":"Animal models of dementia and cognitive dysfunction","volume":"109","author":"Neha","year":"2014","journal-title":"Life Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1258\/jrsm.2008.08k033","article-title":"Why animal studies are often poor predictors of human reactions to exposure","volume":"102","author":"Bracken","year":"2009","journal-title":"J. R. Soc. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"206","DOI":"10.7150\/ijms.5529","article-title":"Systematic Reviews of Animal Models: Methodology versus Epistemology","volume":"10","author":"Greek","year":"2013","journal-title":"Int. J. Med Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: The valley of death across preclinical and clinical divide\u2014Identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl. Med. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1021\/jm990017w","article-title":"Designing libraries with CNS activity","volume":"42","author":"Ajay","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.7326\/0003-4819-105-1-82","article-title":"Blood-Brain Barrier: Interface between Internal Medicine and the Brain","volume":"105","author":"Pardridge","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"ref_101","unstructured":"Alzheimer\u2019s Association (2020). 2020 Alzheimer\u2019s Disease Facts and Figures. Alzheimer\u2019s Dementia, Wiley."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association (2018). 2018 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dementia, Wiley.","DOI":"10.1016\/j.jalz.2018.02.001"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40259-020-00435-w","article-title":"Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015\u20132020","volume":"34","author":"Rolfes","year":"2020","journal-title":"BioDrugs"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/S0140-6736(17)32399-1","article-title":"Why do so many clinical trials of therapies for Alzheimer\u2019s disease fail?","volume":"390","author":"Anderson","year":"2017","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer\u2019s disease: An appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Intern. Med."},{"key":"ref_106","first-page":"S101","article-title":"Why have we failed to achieve neuroprotection in Parkinson\u2019s disease?","volume":"64","author":"Olanow","year":"2008","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"key":"ref_107","first-page":"73","article-title":"A new zebrafish model produced by TILLING of SOD1-related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening","volume":"7","author":"Allen","year":"2013","journal-title":"Dis. Model. Mech."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ana.23780","article-title":"Early interneuron dysfunction in ALS: Insights from a mutant sod1 zebrafish model","volume":"73","author":"McGown","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep24515","article-title":"NaP selective inhibition reverts precocious inter-and motorneurons hyperexcitability in the Sod1-G93R zebrafish ALS model","volume":"6","author":"Benedetti","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10126-018-9857-x","article-title":"Conditional Overexpression of rtn4al in Muscle of Adult Zebrafish Displays Defects Similar to Human Amyotrophic Lateral Sclerosis","volume":"21","author":"Lin","year":"2018","journal-title":"Mar. Biotechnol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s40478-018-0629-7","article-title":"Stable transgenic C9orf72 zebrafish model key aspects of the ALS\/FTD phenotype and reveal novel pathological features","volume":"6","author":"Shaw","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40572-014-0029-5","article-title":"Zebrafish: A Marvel of High-Throughput Biology for 21st Century Toxicology","volume":"1","author":"Bugel","year":"2014","journal-title":"Curr. Environ. Health Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-016-0122-3","article-title":"ZNStress: A high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis","volume":"11","author":"McGown","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00429-009-0237-1","article-title":"Transgenic zebrafish models of neurodegenerative diseases","volume":"214","author":"Sager","year":"2010","journal-title":"Brain Struct. Funct."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.vascn.2018.07.002","article-title":"Zebrafish models: Do we have valid paradigms for depression?","volume":"94","author":"Friend","year":"2018","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tips.2013.12.002","article-title":"Zebrafish as an emerging model for studying complex brain disorders","volume":"35","author":"Kalueff","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1534\/genetics.116.194084","article-title":"Sydney Brenner on the Genetics of Caenorhabditis elegans","volume":"204","author":"Goldstein","year":"2016","journal-title":"Genetics"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/genetics\/77.1.71","article-title":"The genetics of caenorhabditis elegans","volume":"77","author":"Brenner","year":"1974","journal-title":"Genetics"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.2174\/1568026617666170131114401","article-title":"elegans as Model for Drug Discovery","volume":"17","author":"Carretero","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fgene.2014.00085","article-title":"Worming forward: Amyotrophic lateral sclerosis toxicity mechanisms and genetic interactions in Caenorhabditis elegans","volume":"5","author":"Therrien","year":"2014","journal-title":"Front. Genet."},{"key":"ref_121","unstructured":"Walker, G.P. (2021, February 23). Dissecting Age Associated Disease in C. elegans. Available online: https:\/\/digital.wpi.edu\/concern\/student_works\/4f16c444r?locale=en."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JPD-171258","article-title":"Modeling Parkinson\u2019s Disease in C. elegans","volume":"8","author":"Cooper","year":"2018","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fgene.2014.00279","article-title":"Use of Caenorhabditis elegans as a model to study Alzheimer\u2019s disease and other neurodegenerative diseases","volume":"5","author":"Alexander","year":"2014","journal-title":"Front. Genet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tma.2020.05.001","article-title":"Caenorhabditis elegans as a model system for studying aging-associated neurodegenerative diseases","volume":"4","author":"Truttmann","year":"2020","journal-title":"Transl. Med. Aging"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Solana-Manrique, C., Molt\u00f3, M.D., Calap-Quintana, P., Sanz, F.J., Llorens, J.V., and Paricio, N. (2019). Drosophila as a Model System for the Identification of Pharmacological Therapies in Neurodegenerative Diseases. Insights into Human Neurodegeneration: Lessons Learnt from Drosophila, Springer International Publishing.","DOI":"10.1007\/978-981-13-2218-1_15"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.freeradbiomed.2017.04.364","article-title":"Identification of potential therapeutic compounds for Parkinson\u2019s disease using Drosophila and human cell models","volume":"108","author":"Sanz","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e1376","DOI":"10.1002\/wsbm.1376","article-title":"Trends in high-throughput and functional neuroimaging inCaenorhabditis elegans","volume":"9","author":"Cho","year":"2017","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Gosai, S.J., Kwak, J.H., Luke, C.J., Long, O.S., King, D.E., Kovatch, K.J., Johnston, P.A., Shun, T.Y., Lazo, J.S., and Perlmutter, D.H. (2010). Automated High-Content Live Animal Drug Screening Using C. elegans Expressing the Aggregation Prone Serpin \u03b11-antitrypsin Z. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015460"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.1038\/ncomms13023","article-title":"Large-scale microfluidics providing high-resolution and high-throughput screening of Caenorhabditis elegans poly-glutamine aggregation model","volume":"7","author":"Mondal","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.exger.2003.10.020","article-title":"Advantages and disadvantages of Caenorhabditis elegans for aging research","volume":"38","author":"Johnson","year":"2003","journal-title":"Exp. Gerontol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/07924259.2014.940470","article-title":"Using C. elegans for aging research","volume":"59","author":"Tissenbaum","year":"2015","journal-title":"Invertebr. Reprod. Develop."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.pharmthera.2006.05.012","article-title":"Drosophila melanogaster neurobiology, neuropharmacology, and how the fly can inform central nervous system drug discovery","volume":"112","author":"Nichols","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.stemcr.2016.10.001","article-title":"High-Throughput Toxicity and Phenotypic Screening of 3D Human Neural Progenitor Cell Cultures on a Microarray Chip Platform","volume":"7","author":"Nierode","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/17460441.2020.1767579","article-title":"Pluripotent stem cells for neurodegenerative disease modeling: An expert view on their value to drug discovery","volume":"15","author":"Chen","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex Genome Engineering Using CRISPR\/Cas Systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00243848","article-title":"Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson\u2019s disease","volume":"65","author":"Brundin","year":"1986","journal-title":"Exp. Brain Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/hipo.22405","article-title":"Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer\u2019s disease and neuronal loss","volume":"25","author":"Ager","year":"2015","journal-title":"Hippocampus"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1242\/dmm.007237","article-title":"A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis","volume":"4","author":"Kalmar","year":"2011","journal-title":"Dis. Model. Mech."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13024-015-0031-x","article-title":"CRISPR\/Cas9: A powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases","volume":"10","author":"Tu","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s10439-020-02498-w","article-title":"Biomaterials and Culture Systems for Development of Organoid and Organ-on-a-Chip Models","volume":"48","author":"Kosic","year":"2020","journal-title":"Ann. Biomed. Eng."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Lee, H.-K., Sanchez, C.V., Chen, M., Morin, P.J., Wells, J.M., Hanlon, E.B., and Xia, W. (2016). Three Dimensional Human Neuro-Spheroid Model of Alzheimer\u2019s Disease Based on Differentiated Induced Pluripotent Stem Cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163072"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.biomaterials.2013.11.028","article-title":"A 3D Alzheimer\u2019s disease culture model and the induction of P21-activated kinase mediated sensing in iPSC derived neurons","volume":"35","author":"Zhang","year":"2014","journal-title":"Biomaterials"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12987-018-0108-3","article-title":"A perfused human blood\u2013brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport","volume":"15","author":"Wevers","year":"2018","journal-title":"Fluids Barriers CNS"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fphar.2018.00006","article-title":"Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning","volume":"9","author":"Langhans","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-030-11135-9_1","article-title":"Past, Present, and Future of Neuronal Models In Vitro","volume":"Volume 22","author":"Keller","year":"2019","journal-title":"Advances in Neurobiology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.bbrc.2015.12.058","article-title":"Microfluidic technology enhances the potential of human pluripotent stem cells","volume":"473","author":"Gagliano","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"015013","DOI":"10.1088\/1758-5090\/7\/1\/015013","article-title":"Microfluidically supported biochip design for culture of endothelial cell layers with improved perfusion conditions","volume":"7","author":"Raasch","year":"2015","journal-title":"Biofabrication"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.tibtech.2019.04.006","article-title":"Advances in Microfluidic Blood\u2013Brain Barrier (BBB) Models","volume":"37","author":"Oddo","year":"2019","journal-title":"Trends Biotechnol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nbt.2989","article-title":"Microfluidic organs-on-chips","volume":"32","author":"Bhatia","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"051301","DOI":"10.1063\/1.5120555","article-title":"Brain-on-a-chip: A history of development and future perspective","volume":"13","author":"Bang","year":"2019","journal-title":"Biomicrofluidics"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/brv.12626","article-title":"Modelling neurodegenerative diseases with 3D brain organoids","volume":"95","author":"Chang","year":"2020","journal-title":"Biol. Rev."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1039\/C4LC00962B","article-title":"Three-dimensional brain-on-a-chip with an interstitial level of flow and its application as an in vitro model of Alzheimer\u2019s disease","volume":"15","author":"Park","year":"2015","journal-title":"Lab. Chip"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"srep01823","DOI":"10.1038\/srep01823","article-title":"Microfluidic Chemotaxis Platform for Differentiating the Roles of Soluble and Bound Amyloid-\u03b2 on Microglial Accumulation","volume":"3","author":"Cho","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.celrep.2017.12.013","article-title":"Reconstituting Corticostriatal Network on-a-Chip Reveals the Contribution of the Presynaptic Compartment to Huntington\u2019s Disease","volume":"22","author":"Virlogeux","year":"2018","journal-title":"Cell Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrn.2017.107","article-title":"The use of brain organoids to investigate neural development and disease","volume":"18","author":"Kriegstein","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_159","unstructured":"Kaku, M. (2015). The Future of the Mind: The Scientific Quest to Understand, enhance, and Empower the Mind, Doubleday. Anchor Books."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010715-103548","article-title":"Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases","volume":"56","author":"Haston","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_161","first-page":"1","article-title":"Assembly of Human Stem Cell-Derived Cortical Spheroids and Vascular Spheroids to Model 3-D Brain-like Tissues","volume":"9","author":"Song","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13024-019-0347-z","article-title":"Generating microglia from human pluripotent stem cells: Novel in vitro models for the study of neurodegeneration","volume":"14","author":"Speicher","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06684-2","article-title":"Microglia innately develop within cerebral organoids","volume":"9","author":"Ormel","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1474-4422(07)70326-5","article-title":"Strategies to advance translational research into brain barriers","volume":"7","author":"Neuwelt","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00401-018-1815-1","article-title":"Functional morphology of the blood\u2013brain barrier in health and disease","volume":"135","author":"Liebner","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1474-4422(20)30076-4","article-title":"T cells in Alzheimer\u2019s disease: Space invaders","volume":"19","author":"McManus","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: A target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/NMM:7:3:255","article-title":"T-Cells in Alzheimer\u2019s Disease","volume":"7","author":"Town","year":"2005","journal-title":"NeuroMolecular Med."},{"key":"ref_170","first-page":"322","article-title":"An immune-cell signature marks the brain in Alzheimer\u2019s disease","volume":"577","author":"Heneka","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-48538-x","article-title":"Blockade of \u03b14 integrins reduces leukocyte\u2013endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer\u2019s disease","volume":"9","author":"Pietronigro","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2014.01.003","article-title":"Migration of neutrophils targeting amyloid plaques in Alzheimer\u2019s disease mouse model","volume":"35","author":"Baik","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Pandit, R., Chen, L., and G\u00f6tz, J. (2020). The blood-brain barrier: Physiology and strategies for drug delivery. Adv. Drug Deliv. Rev., 1\u201314.","DOI":"10.1016\/j.addr.2019.11.009"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17460441.2020.1696307","article-title":"The impact of chemoinformatics on drug discovery in the pharmaceutical industry","volume":"15","author":"Maggiora","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2019.06.004","article-title":"Advancing Drug Discovery via Artificial Intelligence","volume":"40","author":"Chan","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"122721","DOI":"10.1016\/j.cej.2019.122721","article-title":"Microfluidic synthesis of fatty acid esters: Integration of dynamic combinatorial chemistry and scale effect","volume":"381","author":"He","year":"2020","journal-title":"Chem. Eng. J."},{"key":"ref_177","first-page":"S55","article-title":"How artificial intelligence is changing drug discovery","volume":"557","author":"Fleming","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1039\/b917763a","article-title":"A microfluidic device for a pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) model on a chip","volume":"10","author":"Sung","year":"2010","journal-title":"Lab Chip"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.apsb.2018.04.003","article-title":"Drug metabolism in drug discovery and development","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1089\/adt.2008.150","article-title":"A Robotic Platform for Quantitative High-Throughput Screening","volume":"6","author":"Michael","year":"2008","journal-title":"ASSAY Drug Dev. Technol."}],"container-title":["Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-5354\/8\/2\/30\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:26:52Z","timestamp":1760160412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-5354\/8\/2\/30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":180,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["bioengineering8020030"],"URL":"https:\/\/doi.org\/10.3390\/bioengineering8020030","relation":{},"ISSN":["2306-5354"],"issn-type":[{"value":"2306-5354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]}}}